

3. Advice on susceptibility testing not currently available in the formal recommendations

Topic	Comment
<i>Bacillus</i> spp.	See Andrews J. M. and Wise R. Susceptibility testing <i>Bacillus</i> species. <i>J Antimicrob Chemother</i> 2002; 49 : 1040-42
<i>Helicobacter</i> spp.	See Appendix 3 in version 6.1, Susceptibility testing of <i>Helicobacter pylori</i> , which gives information on the use of Etest and tentative MIC breakpoints
<i>Listeria</i> spp.	SRGA recommendations (same technique as BSAC) are available, but using disc contents that are higher than those used in the UK. This is under review by the Susceptibility Testing Working Party
<i>B. cepacia</i>	This is under review by the Susceptibility Testing Working Party
Topical antibiotics	There are currently no recommendations (other than mupirocin) because there are few published clinical data to support interpretative criteria. However, this is under review by the Susceptibility Testing Working Party and guidance is likely to be developed based on systemic breakpoints when available and epidemiological breakpoints for other agents. This is in line with the views of the European Medicines Evaluation Agency (EMEA)
Susceptibility testing fungi	Not within the remit of the current Susceptibility Testing Working Party. Advice is available from the HPA Fungal Reference Laboratory, Bristol
Susceptibility testing <i>M. tuberculosis</i>	Not within the remit of the current Susceptibility Testing Working Party. Advice is available from the HPA Mycobacterial Reference Laboratory, London